URBANDALE, Iowa, March 7, 2017 /PRNewswire/ -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that Company management will present at the 29th Annual ROTH Conference on Wednesday, March 15, 2017, at 7:00 a.m. Pacific Time. The conference takes place March 12–15, 2017, at The Ritz Carlton, Dana Point, California.
Date: Wednesday, March 15th, 2017
Time: 7:00 a.m. Pacific Time
Location: The Ritz Carlton, Dana Point, California
Therapeutic Focus: Orphan/Rare Diseases
For more information about the conference, contact Robert Haag at firstname.lastname@example.org.
About 29th Annual ROTH Conference
The ROTH conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with close to 500 participating companies and over 4,000 attendees, will feature presentations from hundreds of public and private companies in a variety of sectors including:
- Technology, Internet & Media
- Cleantech, Industrial Growth & Solar
- Oil & Gas / Mining & Minerals
- Business Services
Throughout the three and a half day event, the ROTH Conference will host:
- 10 concurrent tracks of company presentations
- Thousands of 1-on-1 / small group meetings
- Several thematic panel discussions
- A private company track
- Three nights of signature evening entertainment
- ROTH Signature Social Sunday featuring ROTH Ride, Spin, Golf and Tennis events.
This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative, proprietary technologies designed to address unmet medical needs, with an emphasis on rare, emerging and neglected diseases. To find and evaluate unique opportunities, we leverage our extensive relationships with leading scientists, academic institutions and other sources. We provide value-added development capability to accelerate development progress. When scientifically significant benchmarks have been achieved, we will endeavor to partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
Statements in this press release that are not purely historical are forward-looking statements. Forward-looking statements herein include statements regarding Spotlight Innovation's efforts to develop and commercialize its various technologies, and to achieve its stated benchmarks. Actual outcomes and actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties, such as: the inability to finance the planned development of the technologies; the inability to hire appropriate staff to develop the technologies; unforeseen technical difficulties in developing the technologies; the inability to obtain regulatory approval for human use; competitors' therapies proving to be more effective, cheaper or otherwise more preferable; or, the inability to market a product. All of which could, among other things, delay or prevent product release, as well as other factors expressed from time to time in Spotlight Innovation's periodic filings with the Securities and Exchange Commission (SEC). As a result, this press release should be read in conjunction with Spotlight Innovation's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release and Spotlight Innovation undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/spotlight-innovation-to-present-at-29th-annual-roth-conference-on-march-15-2017-300418839.html
SOURCE Spotlight Innovation Inc.